A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer

Thyroid ◽  
2020 ◽  
Vol 30 (4) ◽  
pp. 501-518 ◽  
Author(s):  
Ji Min Oh ◽  
Se Hwan Baek ◽  
Prakash Gangadaran ◽  
Chae Moon Hong ◽  
Ramya Lakshmi Rajendran ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Sodium Iodide ◽  
Radioactive Iodine ◽  
Kinase Inhibitor ◽  
Anaplastic Thyroid Cancer ◽  
Iodine Uptake ◽  
Sodium Iodide Symporter ◽  
Radioactive Iodine Uptake

Selective tyrosine kinase inhibitor, STI571, inhibits growth of p53 mutant anaplastic thyroid cancer cells by inducing S–G2 transition arrest

2003 ◽  
Vol 1258 ◽  
pp. 157-161
Author(s):  
Alexei P Podtcheko ◽  
Satoshi Tsuda ◽  
Akira Ohtsuru ◽  
Vladimir A Saenko ◽  
Junichi KurebayashiI ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Kinase Inhibitor ◽  
Anaplastic Thyroid Cancer ◽  
Thyroid Cancer Cells

scholarly journals The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells

2003 ◽  
Vol 88 (4) ◽  
pp. 1889-1896 ◽  
Author(s):  
Alexei Podtcheko ◽  
Akira Ohtsuru ◽  
Satoshi Tsuda ◽  
Hirouki Namba ◽  
Vladimir Saenko ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Kinase Inhibitor ◽  
Anaplastic Thyroid Cancer ◽  
Thyroid Cancer Cells

Multimodal Treatments and Outcomes for Anaplastic Thyroid Cancer Before and After Tyrosine Kinase Inhibitor Therapy: A Real-World Experience

2021 ◽  
Author(s):  
Jun Park ◽  
Hyun Ae Jung ◽  
Joon Ho Shim ◽  
Woong-Yang Park ◽  
Tae Hyuk Kim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Effective Treatment ◽  
Cause Of Death ◽  
Real World ◽  
Distant Metastasis ◽  
Kinase Inhibitor ◽  
Therapy Group ◽  
Anaplastic Thyroid Cancer

Background: Anaplastic thyroid cancer (ATC) has dismal prognosis, and there is no effective treatment. We aimed to evaluate the efficacy of tyrosine kinase inhibitor (TKI) therapy in real world clinic, and to suggest the most effective treatment modality according to the combination of treatments. Methods: This retrospective study evaluated clinical outcomes and cause of death with multimodal treatments in patients with ATC at Samsung Medical Center. Results: A total of 120 patients received anti-cancer treatment for ATC. Seventy-seven (64.2%) patients underwent surgery, 64 (53.3%) received radiotherapy, 29 (24.2%) received cytotoxic chemotherapy, and 19 (15.8%) received TKI therapy. In the TKI therapy group, 8 achieved partial response (3 with lenvatinib and 5 with dabrafenib plus trametinib), and 2 patients with lenvatinib showed stable disease. Median progression-free survival (PFS) of the TKI therapy group was 2.7 months (range: 0.1-12.7) and their median overall survival (OS) was 12.4 months (range: 1.7-47.7). Patients who received surgery or radiotherapy for local control showed superior OS than those who did not. In a multivariate analysis, surgery, TKI therapy, younger age, and no distant metastasis were associated with favorable OS. The combination of surgery, radiotherapy, and TKI therapy (median OS: 34.3 months, 6-month survival rates: 77.8%) was the most effective. Compared to the era without TKI therapy, distant metastasis has recently become the major cause of death in ATC over airway problems. Conclusions: Multimodality treatment including TKI therapy demonstrated prolonged survival with dabrafenib plus trametinib as the most effective therapeutic option demonstrated for BRAF mutant ATC patients.

Sign in / Sign up

Export Citation Format

Share Document